Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
In 290 Chinese patients with advanced squamous NSCLC after platinum chemotherapy, sintilimab vs docetaxel improved median OS (11.79 vs 8.25 months; HR 0.74; 280 analysed) and PFS, with fewer grade ≥3 treatment-related adverse events (18.1% vs 36.2%).
RCTn = 290
Shi et al. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)In 147 adults with primary biliary cholangitis and moderate-to-severe itch, linerixibat (20–180 mg daily) cut worst daily itch by ≥2 points at week 16 but not significantly more than placebo; post hoc analyses suggested dose-related benefit. Diarrhoea rose with dose.
Secondary analysisn = 147
Levy et al. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus